Generalized vitiligo is an autoimmune disorder characterized by acquired white patches of skin and overlying hair due to loss of melanocytes from these areas. Depigmentation is progressive and disfiguring, often resulting in significant psychological trauma. Vitiligo is the most common disorder of pigmentation, with frequency of approximately 0.5% in most populations. Family clustering of cases is not uncommon, in a non-Mendelian pattern suggestive of multifactorial, polygenic inheritance involving both genetic and non-genetic factors. Furthermore, in about half of families vitiligo is associated with autoimmune thyroid disease, pernicious anemia, Addison's disease, lupus, and perhaps inflammatory bowel disease, in both probands and their relatives, indicating that these autoimmune diseases share common etiologic factors, most likely genetic. During the current grant period we surveyed two vitiligo patient groups, the Vitiligo Society (UK) and the National Vitiligo Foundation (USA), ascertaining > 3300 probands, and we subsequently collected and genotyped DNA samples from 94 multiplex Caucasian vitiligo families from this group. By genome-wide genetic linkage analyses, we detected a number of putative linkage signals genome-wide, 3 of which meet genomewide criteria for ' significant' linkage; one of these (AIS1, on 1p) has now been confirmed, showing dominant linkage in larger, autoimmunity-associated vitiligo families. To confirm some of these linkage signals, and to detect others, we now propose to collect and genotype samples from a replicate cohort of 33 larger amd 61 smaller Caucasian families. Confirmed linkage signals will be fine-mapped to determine which can be more finely resolved and linkage signal strength improved. A major aim is the identification of AIS1 by classic positional cloning utilizing large AIS1-linked families. We have already tested a number of genes in the AIS1 interval, and have found potential variants in the FOXD3 promoter that will be now tested for their effect on FOXD3 transcription. Additional patients will be searched for mutations in FOXD3 and in other genes if FOXD3 appears to not be AIS1. A final, related aim to identify one or more additional vitiligo susceptibility genes, depending on linkage results obtained. The long-term significance of this work may be to develop specific approaches to disease therapy and prevention and to apply those modalities to patients at high genetic risk.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR045584-08
Application #
7251922
Study Section
Special Emphasis Panel (ZRG1-ACTS (01))
Program Officer
Lapham, Cheryl K
Project Start
1999-09-01
Project End
2009-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
8
Fiscal Year
2007
Total Cost
$465,191
Indirect Cost
Name
University of Colorado Denver
Department
Genetics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Spritz, Richard A; Andersen, Genevieve H L (2017) Genetics of Vitiligo. Dermatol Clin 35:245-255
Zhai, Z; Liu, W; Kaur, M et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820-3830
Jin, Ying; Andersen, Genevieve; Yorgov, Daniel et al. (2016) Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet 48:1418-1424
Cavalli, Giulio; Hayashi, Masahiro; Jin, Ying et al. (2016) MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A 113:1363-8
Hayashi, Masahiro; Jin, Ying; Yorgov, Daniel et al. (2016) Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A 113:1357-62
Dinarello, Charles A; Nold-Petry, Claudia; Nold, Marcel et al. (2016) Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol 46:1067-81
Nold-Petry, Claudia A; Lo, Camden Y; Rudloff, Ina et al. (2015) IL-37 requires the receptors IL-18R? and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 16:354-65
Cohen, Idan; Idan, Cohen; Rider, Peleg et al. (2015) IL-1? is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity. Sci Rep 5:14756
Michels, Meta; de Mast, Quirijn; Netea, Mihai G et al. (2015) Normal free interleukin-18 (IL-18) plasma levels in dengue virus infection and the need to measure both total IL-18 and IL-18 binding protein levels. Clin Vaccine Immunol 22:650-5
Cavalli, Giulio; Dinarello, Charles A (2015) Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 54:2134-44

Showing the most recent 10 out of 66 publications